Get the SPI Wire

Aptevo Therapeutics Inc.

NASDAQ:APVO
Annual Meeting

of Shareholders

MEETING DATE

09/22/2026
DEF 14A FILED
08/31/2026
PUBLISHED
08/31/2026 9:29 pm
TIME TO PUBLISH
09/02/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:APVO · CUSIP 03835L207 · CLASS Common Stock · CIK 0001671584

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

2
FOR
2
AGAINST
0
WITHHOLD
4
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To approve an amendment and restatement of our Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to include previous amendments to the Certificate of Incorporation and the designation of Series A Junior Participating Preferred Stock (the “Series A Preferred Stock”) and to make certain other technical and administrative changes.
other
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the amendment incorporates previous amendments and makes technical and administrative changes.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), and/or securities convertible into or exercisable for Common Stock, that equals 20% or more of the Common Stock or 20% or more of the voting power outstanding before the issuance, including Common Stock (i) issuable upon the exercise of the common stock purchase warrants (the “Inducement Warrants”), issued and sold in a private placement pursuant to Warrant Inducement and Reload Letters, dated as of August 12, 2026, by and among the Company and the holder parties thereto, and (ii) issuable upon the exercise of the common stock purchase warrants (the “Common Warrants”) that were issued and sold in private placement transactions pursuant to that certain Securities Purchase Agreement, dated as of August 12, 2026, by and among the Company and the purchaser parties thereto.
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states current stockholders will own a smaller percent interest and have less ability to influence decisions.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve the Aptevo Therapeutics Inc. Fifth Amended and Restated 2018 Stock Incentive Plan.
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states 152,360 shares remaining are not sufficient for 2026 grants to senior management and employees.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To authorize an adjournment of the meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1, Proposal 2 or Proposal 3.
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states the meeting could be adjourned even after enough votes were received to defeat proposals.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

49159a081e5e7e1d041acd58e0423f26cc245d16faf844dbcd7ed576582cd3de

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates